Clinical Trials - January 12, 2015
Orphazyme Raises Funds for Trials
Danish biotech company Orphazyme raised a €20 million ($24 million US) B round to pay for its work on rare lysosomal storage disorders as it moves toward Phase II trials. Investors included Novo Nordisk’s venture arm. Orphazyme’s lead candidate, Orph002, is a treatment for Niemann-Pick disease type C (NPC), a rare disorder in which cholesterol […]
Financing - December 16, 2014
BenGenBio Raises NOK90 Million
BerGenBio AS, a Norwegian biopharmaceutical company focused on developing medications for aggressive drug- resistant cancers, announced that it has raised NOK90 million (c. $15 million) in a private placing from new and existing investors. BerGenBio will use the proceeds from the financing to support the development of its pipeline of innovative cancer therapeutics, in particular an enlarged […]
